PIII Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of -5.49% compared to P3 Health Partners's net margin of 1.08%. P3 Health Partners's return on equity of -53.56% beat Astrana Health's return on equity of 7.09%.

P3 Health Partners has a consensus price target of $8.00, signalling upside risk potential of 29.66%. On the other hand Astrana Health has an analysts' consensus of $47.8889 which suggests that it could grow by 99.54%. Given that Astrana Health has higher upside potential than P3 Health Partners, analysts believe Astrana Health is more attractive than P3 Health Partners.

P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Astrana Health has a beta of 0.849, suggesting its less volatile than the S&P 500 by 15.081%.

P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners pays -- of its earnings as a dividend. Astrana Health pays out 9.35% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

P3 Health Partners quarterly revenues are $373.2M, which are smaller than Astrana Health quarterly revenues of $620.4M. P3 Health Partners's net income of -$20.5M is lower than Astrana Health's net income of $6.7M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Astrana Health's PE ratio is 33.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.01x versus 0.51x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Biote has a net margin of -5.49% compared to P3 Health Partners's net margin of 28%. P3 Health Partners's return on equity of -53.56% beat Biote's return on equity of --.

P3 Health Partners has a consensus price target of $8.00, signalling upside risk potential of 29.66%. On the other hand Biote has an analysts' consensus of $6.40 which suggests that it could grow by 59.55%. Given that Biote has higher upside potential than P3 Health Partners, analysts believe Biote is more attractive than P3 Health Partners.

P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners pays -- of its earnings as a dividend. Biote pays out 150.27% of its earnings as a dividend.

P3 Health Partners quarterly revenues are $373.2M, which are larger than Biote quarterly revenues of $49M. P3 Health Partners's net income of -$20.5M is lower than Biote's net income of $13.7M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Biote's PE ratio is 6.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.01x versus 0.70x for Biote. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of -5.49% compared to P3 Health Partners's net margin of 3.55%. P3 Health Partners's return on equity of -53.56% beat Cryo-Cell International's return on equity of --.

P3 Health Partners has a consensus price target of $8.00, signalling upside risk potential of 29.66%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 66.99%. Given that Cryo-Cell International has higher upside potential than P3 Health Partners, analysts believe Cryo-Cell International is more attractive than P3 Health Partners.

P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.015%.

P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 12.77% to investors and pays a quarterly dividend of $0.15 per share. P3 Health Partners pays -- of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.

P3 Health Partners quarterly revenues are $373.2M, which are larger than Cryo-Cell International quarterly revenues of $8M. P3 Health Partners's net income of -$20.5M is lower than Cryo-Cell International's net income of $282.9K. Notably, P3 Health Partners's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is 509.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.01x versus 1.30x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell has a net margin of -5.49% compared to P3 Health Partners's net margin of -2.6%. P3 Health Partners's return on equity of -53.56% beat Omnicell's return on equity of 1.73%.

P3 Health Partners has a consensus price target of $8.00, signalling upside risk potential of 29.66%. On the other hand Omnicell has an analysts' consensus of $39.83 which suggests that it could grow by 40.41%. Given that Omnicell has higher upside potential than P3 Health Partners, analysts believe Omnicell is more attractive than P3 Health Partners.

P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Omnicell has a beta of 0.780, suggesting its less volatile than the S&P 500 by 22.026%.

P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners pays -- of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.

P3 Health Partners quarterly revenues are $373.2M, which are larger than Omnicell quarterly revenues of $269.7M. P3 Health Partners's net income of -$20.5M is lower than Omnicell's net income of -$7M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Omnicell's PE ratio is 61.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.01x versus 1.16x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.